{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:33:08Z","timestamp":1759743188146},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,10,10]],"date-time":"2013-10-10T00:00:00Z","timestamp":1381363200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s10689-013-9690-3","type":"journal-article","created":{"date-parts":[[2013,10,9]],"date-time":"2013-10-09T08:26:53Z","timestamp":1381307213000},"page":"173-180","source":"Crossref","is-referenced-by-count":12,"title":["RAD51 135G>C and TP53 Arg72Pro polymorphisms and susceptibility to breast cancer in Serbian women"],"prefix":"10.1007","volume":"13","author":[{"given":"Ana M.","family":"Krivokuca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emina J.","family":"Malisic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelena D.","family":"Dobricic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ksenija V.","family":"Brotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena R.","family":"Cavic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radmila N.","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zorica I.","family":"Tomasevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjana V.","family":"Brankovic-Magic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,10]]},"reference":[{"key":"9690_CR1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s13402-011-0010-3","volume":"34","author":"P Groep Van der","year":"2011","unstructured":"Van der Groep P, Van der Wall E, Van Diest PJ (2011) Pathology of hereditary breast cancer. Cell Oncol 34:71\u201388","journal-title":"Cell Oncol"},{"key":"9690_CR2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/1471-2407-7-163","volume":"7","author":"S Margolin","year":"2007","unstructured":"Margolin S, Eiberg H, Lindblom A, Bisgaard ML (2007) CHEK2 1100delC is prevalent in Swedish early onset familial breast cancer. BMC Cancer 7:163","journal-title":"BMC Cancer"},{"key":"9690_CR3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/bcr2099","volume":"10","author":"GB Byrnes","year":"2008","unstructured":"Byrnes GB, Southey MC, Hopper JL (2008) Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories? Breast Cancer Res 10:208","journal-title":"Breast Cancer Res"},{"issue":"1","key":"9690_CR4","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1158\/1055-9965.EPI-08-0416","volume":"18","author":"O Fletcher","year":"2009","unstructured":"Fletcher O, Johnson N, Santos Silva I, Kilpivaara O, Aittomaki K, Blomqvist C et al (2009) Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2*1100delC in 1,828 bilateral breast cancers and 7,030 controls. Cancer Epidemiol Biomarkers Prev 18(1):230\u2013234","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"9690_CR5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/107327480501200210","volume":"12","author":"V Dapic","year":"2005","unstructured":"Dapic V, Carvalho MA, Monteiro A (2005) Breast cancer susceptibility and the DNA damage response. Cancer Control J 12(2):127\u2013136","journal-title":"Cancer Control J"},{"key":"9690_CR6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10549-006-9364-z","volume":"103","author":"S Costa","year":"2007","unstructured":"Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R et al (2007) DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility: a study on a Portuguese population. Breast Cancer Res Treat 103:209\u2013217","journal-title":"Breast Cancer Res Treat"},{"key":"9690_CR7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s100380050199","volume":"45","author":"M Kato","year":"2000","unstructured":"Kato M, Yano K, Matsuo F, Saito H, Katagiri T, Kurumizaka F et al (2000) Identification of Rad51 alteration in patients with bilateral breast cancer. J Hum Genet 45:133\u2013137","journal-title":"J Hum Genet"},{"key":"9690_CR8","first-page":"955","volume":"10","author":"W Wang","year":"2001","unstructured":"Wang W, Spurdle A, Kolachana P, Bove B, Modan B, Ebbers S et al (2001) A single nucleotide polymorphism in the 5\u2032untranslated region of RAD51 and risk of cancer among BRCA1\/2 mutation carriers. Cancer Epidemiol Biomark Prev 10:955\u2013960","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"9690_CR9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","volume":"137","author":"K Vousden","year":"2009","unstructured":"Vousden K, Prives C (2009) Blinded by the Light: the growing complexity of p53. Cell 137:413\u2013431","journal-title":"Cell"},{"key":"9690_CR10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/bcr426","volume":"4","author":"M Gasco","year":"2002","unstructured":"Gasco M, Shami S, Crook T (2002) The p53 pathway in breast cancer. Breast Cancer Res 4:70\u201376","journal-title":"Breast Cancer Res"},{"key":"9690_CR11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrc2584","volume":"9","author":"C Whibley","year":"2009","unstructured":"Whibley C, Pharoah P, Hollstein M (2009) p53 polymorphisms: cancer implications. Nat Rev 9:95\u2013110","journal-title":"Nat Rev"},{"key":"9690_CR12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/2041-9414-1-15","volume":"1","author":"T Bohgaki","year":"2010","unstructured":"Bohgaki T, Bohgaki M, Hakem R (2010) DNA double-strand break signaling and human disorders. Genome Integr 1:15","journal-title":"Genome Integr"},{"key":"9690_CR13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.canlet.2004.08.009","volume":"218","author":"C Richardson","year":"2005","unstructured":"Richardson C (2005) RAD51, genomic stability, and tumorigenesis. Cancer Lett 218:127\u2013139","journal-title":"Cancer Lett"},{"key":"9690_CR14","doi-asserted-by":"crossref","first-page":"R26","DOI":"10.1186\/bcr1415","volume":"8","author":"F Lose","year":"2006","unstructured":"Lose F, Lovelock P, Chenevix-Trench G, Mann GJ, Pupo GM, Spurdle AB et al (2006) Variation in the RAD51 gene and familial breast cancer. Breast Cancer Res 8:R26","journal-title":"Breast Cancer Res"},{"key":"9690_CR15","first-page":"4564","volume":"59","author":"C Schmutte","year":"1999","unstructured":"Schmutte C, Tombline G, Rhiem K, Sadoff MM, Schmutzler R, von Deimling A et al (1999) Characterization of the human Rad51 genomic locus and examination of tumors with 15q14\u201315 loss of heterozygosity (LOH). Cancer Res 59:4564\u20134569","journal-title":"Cancer Res"},{"key":"9690_CR16","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.1073\/pnas.93.13.6236","volume":"93","author":"T Tsuzuki","year":"1996","unstructured":"Tsuzuki T, Fujii Y, Sakumi K, Tominaga Y, Nakao K, Sekiguchi M et al (1996) Targeted disruption of the Rad5\u00a0l gene leads to lethality in embryonic mice. Proc Natl Acad Sci USA 93:6236\u20136240","journal-title":"Proc Natl Acad Sci USA"},{"key":"9690_CR17","first-page":"219","volume":"62","author":"E Raderschall","year":"2002","unstructured":"Raderschall E, Stout K, Freier S, Suckow V, Schweiger S, Haaf T (2002) Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res 62:219\u2013225","journal-title":"Cancer Res"},{"key":"9690_CR18","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s10549-010-0995-8","volume":"125","author":"LB Gao","year":"2011","unstructured":"Gao LB, Pan XM, Li LJ, Liang WB, Zhu Y, Zhang LS et al (2011) RAD51 135G\/C polymorphism and breast cancer risk: a meta-analysis from 21 studies. Breast Cancer Res Treat 125:827\u2013835","journal-title":"Breast Cancer Res Treat"},{"key":"9690_CR19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10549-010-0922-z","volume":"125","author":"H Sun","year":"2011","unstructured":"Sun H, Bai J, Chen F, Jin Y, Yu Y, Jin L, Fu S (2011) RAD51 G135C polymorphism is associated with breast cancer susceptibility: a meta-analysis involving 22,399 subjects. Breast Cancer Res Treat 125:157\u2013161","journal-title":"Breast Cancer Res Treat"},{"key":"9690_CR20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cancergencyto.2007.05.024","volume":"178","author":"L Jara","year":"2007","unstructured":"Jara L, Acevedo M, Blanco R, Castro V, Bravo T, Gomez F et al (2007) RAD51 135G>C polymorphism and risk of familial breast cancer in a South American population. Cancer Genet Cytogenet 178:65\u201369","journal-title":"Cancer Genet Cytogenet"},{"key":"9690_CR21","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1086\/522611","volume":"81","author":"A Antoniou","year":"2007","unstructured":"Antoniou A, Sinilnikova O, Simard J, Leone M, Dumon M, Neuhausen S (2007) RAD51 135G>C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 81:1186\u20131200","journal-title":"Am J Hum Genet"},{"key":"9690_CR22","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00109-007-0221-2","volume":"85","author":"J Teodoro","year":"2007","unstructured":"Teodoro J, Evans S, Green M (2007) Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med 85:1175\u20131186","journal-title":"J Mol Med"},{"key":"9690_CR23","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jmb.2003.12.050","volume":"336","author":"D Yoon","year":"2004","unstructured":"Yoon D, Wang Y, Stapleford K, Wiesmuller L, Chen J (2004) p53 inhibits strand exchange and replication fork regression promoted by human Rad51. J Mol Biol 336:639\u2013654","journal-title":"J Mol Biol"},{"key":"9690_CR24","first-page":"875","volume":"3","author":"A Al-Qasem","year":"2012","unstructured":"Al-Qasem A, Toulimat M, Tulbah A, Elkum N, Al-Tweigeri T, Aboussekhra A (2012) The p53 codon 72 polymorphism is associated with risk and early onset of breast cancer among Saudi women. Oncol Lett 3:875\u2013878","journal-title":"Oncol Lett"},{"issue":"10","key":"9690_CR25","doi-asserted-by":"crossref","first-page":"e47325","DOI":"10.1371\/journal.pone.0047325","volume":"7","author":"K Proestling","year":"2012","unstructured":"Proestling K, Hebar A, Pruckner N, Marton E, Vinatzer U, Schreiber M (2012) The pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk. PLOS 7(10):e47325","journal-title":"PLOS"},{"key":"9690_CR26","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/sj.bjc.6602451","volume":"92","author":"T Ohayon","year":"2005","unstructured":"Ohayon T, Gershoni-Baruch R, Papa MZ, Distelman Menachem T, Eisenberg Barzilai S, Friedman E (2005) The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer 92:1144\u20131148","journal-title":"Br J Cancer"},{"key":"9690_CR27","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.cdp.2006.09.007","volume":"30","author":"A Damin","year":"2006","unstructured":"Damin A, Frazzon A, Damin D, Roehe A, Hermes V, Zettler C, Alexandre C (2006) Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detect Prev 30:523\u2013529","journal-title":"Cancer Detect Prev"},{"key":"9690_CR28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2407-8-32","volume":"8","author":"S Costa","year":"2008","unstructured":"Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, Schmitt F (2008) Importance of TP53 codon 72 and intron 3 duplication 16\u00a0bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 8:32","journal-title":"BMC Cancer"},{"key":"9690_CR29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1756-9966-28-115","volume":"28","author":"W Zhuo","year":"2009","unstructured":"Zhuo W, Zhang Y, Xiang Z, Cai L, Chen Z (2009) Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controls. J Exp Clin Cancer Res 28:115","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-013-9690-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10689-013-9690-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-013-9690-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T14:58:23Z","timestamp":1564498703000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10689-013-9690-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,10]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["9690"],"URL":"https:\/\/doi.org\/10.1007\/s10689-013-9690-3","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"value":"1389-9600","type":"print"},{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,10]]}}}